344 related articles for article (PubMed ID: 33176391)
1. Time trends in diabetes medication prescription and factors associated with metformin discontinuation in people with newly diagnosed type 2 diabetes: A national population-based study.
Aguadé AS; Gastaldi-Ménager C; Fontaine P; Karsenty D; Fagot-Campagna A; Amadou C
Diabet Med; 2021 Jul; 38(7):e14457. PubMed ID: 33176391
[TBL] [Abstract][Full Text] [Related]
2. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians.
Boyc KS; Yurgin N; Lage MJ
Adv Ther; 2007; 24(4):803-13. PubMed ID: 17901029
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study.
Kosjerina V; Carstensen B; Jørgensen ME; Brock B; Christensen HR; Rungby J; Andersen GS
Lancet Healthy Longev; 2021 Sep; 2(9):e561-e570. PubMed ID: 36098008
[TBL] [Abstract][Full Text] [Related]
4. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes.
Cohen FJ; Neslusan CA; Conklin JE; Song X
Diabetes Care; 2003 Jun; 26(6):1847-51. PubMed ID: 12766121
[TBL] [Abstract][Full Text] [Related]
5. [Anti-Diabetic Medication During the First Four Years of Treatment. A Study Based on Claims Data].
Lappe V; Köster I; Schubert I
Dtsch Med Wochenschr; 2017 Jan; 142(1):e1-e9. PubMed ID: 28056470
[TBL] [Abstract][Full Text] [Related]
6. Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand.
Horsburgh S; Sharples K; Barson D; Zeng J; Parkin L
PLoS One; 2021; 16(4):e0250289. PubMed ID: 33882106
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.
Campbell DJT; Campbell DB; Ogundeji Y; Au F; Beall R; Ronksley PE; Quinn AE; Manns BJ; Hemmelgarn BR; Tonelli M; Spackman E
Diabet Med; 2021 Sep; 38(9):e14622. PubMed ID: 34133781
[TBL] [Abstract][Full Text] [Related]
9. Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study.
Liu CH; Chen ST; Chang CH; Chuang LM; Lai MS
Public Health; 2017 Nov; 152():20-27. PubMed ID: 28719837
[TBL] [Abstract][Full Text] [Related]
10. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
[TBL] [Abstract][Full Text] [Related]
11. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Liao EP
Am J Med; 2012 Oct; 125(10):S1-2. PubMed ID: 22998891
[TBL] [Abstract][Full Text] [Related]
12. Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada.
Kim T; Campbell DB; Au F; Ronksley PE; Weaver RG; Campbell DJT
Diabetes Obes Metab; 2024 Apr; 26(4):1234-1243. PubMed ID: 38164697
[TBL] [Abstract][Full Text] [Related]
13. Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis.
Seo HJ; Oh HS
Epidemiol Health; 2021; 43():e2021103. PubMed ID: 34922421
[TBL] [Abstract][Full Text] [Related]
14. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
15. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Wood SJ; Magliano DJ; Bell JS; Shaw JE; Keen CS; Ilomäki J
Diabet Med; 2020 Aug; 37(8):1367-1373. PubMed ID: 31557346
[TBL] [Abstract][Full Text] [Related]
17. The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015.
Wang X; Cao Y; Wu Y; Yang C; Song J; Tian Y; Wang M; Li M; Wu Y; Hu Y
Medicine (Baltimore); 2019 Feb; 98(8):e14370. PubMed ID: 30813137
[TBL] [Abstract][Full Text] [Related]
18. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cho YY; Cho SI
Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
[TBL] [Abstract][Full Text] [Related]
19. Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes.
Vaughan EM; Johnston CA; Hyman DJ; Hernandez DC; Hemmige V; Foreyt JP
J Prim Care Community Health; 2017 Oct; 8(4):305-311. PubMed ID: 29216790
[TBL] [Abstract][Full Text] [Related]
20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
